Skip to main content
Erschienen in: Heart Failure Reviews 2/2019

28.11.2018

Updates in heart failure 30-day readmission prevention

verfasst von: David Goldgrab, Kathir Balakumaran, Min Jung Kim, Sara R. Tabtabai

Erschienen in: Heart Failure Reviews | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Heart failure (HF) and HF 30-day readmission rates have been a major focus of efforts to reduce health care cost in the recent era. Since the implementation of the Affordable Care Act (ACA) in 2012 and the Hospital Readmission Reduction Program (HRRP), concerted efforts have focused on reduction of 30-day HF readmissions and other admission diagnoses targeted by the HRRP. Hospitals and organizations have instituted wide-ranging programs to reduce short-term readmissions, but the data supporting these programs is often mixed. In this review, we will discuss the challenges associated with reducing HF readmissions and summarize the rationale and effect of specific programs on HF 30-day readmission rates, ranging from medical therapy and adherence to remote hemodynamic monitoring. Finally, we will review the effect that the focus on reducing 30-day HF readmissions has had on the care of the HF patient.
Literatur
2.
Zurück zum Zitat Dharmarajan K, Wang Y, Lin Z, Normand SLT, Ross JS, Horwitz LI, Desai NR, Suter LG, Drye EE, Bernheim SM, Krumholz HM (2017) Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA - J Am Med Assoc. 318(3):270–278. https://doi.org/10.1001/jama.2017.8444 CrossRef Dharmarajan K, Wang Y, Lin Z, Normand SLT, Ross JS, Horwitz LI, Desai NR, Suter LG, Drye EE, Bernheim SM, Krumholz HM (2017) Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA - J Am Med Assoc. 318(3):270–278. https://​doi.​org/​10.​1001/​jama.​2017.​8444 CrossRef
5.
Zurück zum Zitat Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogdon JG, American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Hear Fail 6(3):606–619. https://doi.org/10.1161/HHF.0b013e318291329a CrossRef Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogdon JG, American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Hear Fail 6(3):606–619. https://​doi.​org/​10.​1161/​HHF.​0b013e318291329a​ CrossRef
13.
Zurück zum Zitat Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327(10):669–677. https://doi.org/10.1056/NEJM199209033271001 CrossRefPubMed Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327(10):669–677. https://​doi.​org/​10.​1056/​NEJM199209033271​001 CrossRefPubMed
16.
Zurück zum Zitat Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321. https://doi.org/10.1056/NEJMoa030207 CrossRefPubMed Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321. https://​doi.​org/​10.​1056/​NEJMoa030207 CrossRefPubMed
17.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. Circulation 136(6):e137–e161. https://doi.org/10.1161/CIR.0000000000000509 CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. Circulation 136(6):e137–e161. https://​doi.​org/​10.​1161/​CIR.​0000000000000509​ CrossRefPubMed
18.
Zurück zum Zitat McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077 CrossRefPubMed McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://​doi.​org/​10.​1056/​NEJMoa1409077 CrossRefPubMed
21.
Zurück zum Zitat Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34–42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255 CrossRefPubMed Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34–42. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​114.​013255 CrossRefPubMed
22.
Zurück zum Zitat Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38(24):1883–1890. https://doi.org/10.1093/eurheartj/ehx026 CrossRefPubMed Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38(24):1883–1890. https://​doi.​org/​10.​1093/​eurheartj/​ehx026 CrossRefPubMed
23.
Zurück zum Zitat Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS (2017) Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 19(11):1414–1423. https://doi.org/10.1002/ejhf.887 CrossRefPubMed Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS (2017) Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 19(11):1414–1423. https://​doi.​org/​10.​1002/​ejhf.​887 CrossRefPubMed
25.
Zurück zum Zitat Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A, on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2016) European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18(6):613–625. https://doi.org/10.1002/ejhf.566 CrossRefPubMed Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A, on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2016) European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18(6):613–625. https://​doi.​org/​10.​1002/​ejhf.​566 CrossRefPubMed
26.
Zurück zum Zitat Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease the AMETHYST-DN randomized clinical trial. JAMA - J Am Med Assoc 314(2):151–161. https://doi.org/10.1001/jama.2015.7446 CrossRef Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease the AMETHYST-DN randomized clinical trial. JAMA - J Am Med Assoc 314(2):151–161. https://​doi.​org/​10.​1001/​jama.​2015.​7446 CrossRef
29.
Zurück zum Zitat Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M (2004) Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial. J Am Coll Cardiol 43(9):1534–1541. https://doi.org/10.1016/j.jacc.2003.12.040 CrossRefPubMed Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M (2004) Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial. J Am Coll Cardiol 43(9):1534–1541. https://​doi.​org/​10.​1016/​j.​jacc.​2003.​12.​040 CrossRefPubMed
36.
38.
Zurück zum Zitat Asch DA, Troxel AB, Stewart WF, Sequist TD, Jones JB, Hirsch AMG, Hoffer K, Zhu J, Wang W, Hodlofski A, Frasch AB, Weiner MG, Finnerty DD, Rosenthal MB, Gangemi K, Volpp KG (2015) Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial. JAMA - J Am Med Assoc 314(18):1926–1935. https://doi.org/10.1001/jama.2015.14850 CrossRef Asch DA, Troxel AB, Stewart WF, Sequist TD, Jones JB, Hirsch AMG, Hoffer K, Zhu J, Wang W, Hodlofski A, Frasch AB, Weiner MG, Finnerty DD, Rosenthal MB, Gangemi K, Volpp KG (2015) Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial. JAMA - J Am Med Assoc 314(18):1926–1935. https://​doi.​org/​10.​1001/​jama.​2015.​14850 CrossRef
39.
Zurück zum Zitat Volpp KG, Troxel AB, Mehta SJ, Norton L, Zhu J, Lim R, Wang W, Marcus N, Terwiesch C, Caldarella K, Levin T, Relish M, Negin N, Smith-McLallen A, Snyder R, Spettell CM, Drachman B, Kolansky D, Asch DA (2017) Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction the heartstrong randomized clinical trial. JAMA Intern Med 177(8):1093–1101. https://doi.org/10.1001/jamainternmed.2017.2449 CrossRefPubMedPubMedCentral Volpp KG, Troxel AB, Mehta SJ, Norton L, Zhu J, Lim R, Wang W, Marcus N, Terwiesch C, Caldarella K, Levin T, Relish M, Negin N, Smith-McLallen A, Snyder R, Spettell CM, Drachman B, Kolansky D, Asch DA (2017) Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction the heartstrong randomized clinical trial. JAMA Intern Med 177(8):1093–1101. https://​doi.​org/​10.​1001/​jamainternmed.​2017.​2449 CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Böhm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, Klein G, Gerritse B, Monteiro J, Israel C, Bimmel D, Käab S, Huegl B, Brachmann J, OptiLink HF Study Investigators (2016) Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J 37(41):3154–3163. https://doi.org/10.1093/eurheartj/ehw099 CrossRefPubMed Böhm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, Klein G, Gerritse B, Monteiro J, Israel C, Bimmel D, Käab S, Huegl B, Brachmann J, OptiLink HF Study Investigators (2016) Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J 37(41):3154–3163. https://​doi.​org/​10.​1093/​eurheartj/​ehw099 CrossRefPubMed
43.
Zurück zum Zitat Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, Zile MR, Smith AL, Smart FW, O'Shaughnessy MA, Jessup ML, Sparks B, Naftel DL, Stevenson LW, COMPASS-HF Study Group (2008) Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure. The COMPASS-HF study. J Am Coll Cardiol 51(11):1073–1079. https://doi.org/10.1016/j.jacc.2007.10.061 CrossRefPubMed Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, Zile MR, Smith AL, Smart FW, O'Shaughnessy MA, Jessup ML, Sparks B, Naftel DL, Stevenson LW, COMPASS-HF Study Group (2008) Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure. The COMPASS-HF study. J Am Coll Cardiol 51(11):1073–1079. https://​doi.​org/​10.​1016/​j.​jacc.​2007.​10.​061 CrossRefPubMed
45.
Zurück zum Zitat Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, Tritto I, Zannad F, Girerd N (2015) Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail 17(11):1172–1181. https://doi.org/10.1002/ejhf.344 CrossRefPubMed Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, Tritto I, Zannad F, Girerd N (2015) Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail 17(11):1172–1181. https://​doi.​org/​10.​1002/​ejhf.​344 CrossRefPubMed
46.
Zurück zum Zitat Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF (2011) Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) linked to Medicare claims. Circ Hear Fail 4(5):628–636. https://doi.org/10.1161/CIRCHEARTFAILURE.111.962290 CrossRef Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF (2011) Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) linked to Medicare claims. Circ Hear Fail 4(5):628–636. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​111.​962290 CrossRef
47.
Zurück zum Zitat Hamatani Y, Nagai T, Shiraishi Y, Kohsaka S, Nakai M, Nishimura K, Kohno T, Nagatomo Y, Asaumi Y, Goda A, Mizuno A, Yasuda S, Ogawa H, Yoshikawa T, Anzai T, Investigators for the WET-NaDEF Collaboration Project (2018) Long-term prognostic significance of plasma B-type natriuretic peptide level in patients with acute heart failure with reduced, mid-range, and preserved ejection fractions. Am J Cardiol 121(6):731–738. https://doi.org/10.1016/j.amjcard.2017.12.012 CrossRefPubMed Hamatani Y, Nagai T, Shiraishi Y, Kohsaka S, Nakai M, Nishimura K, Kohno T, Nagatomo Y, Asaumi Y, Goda A, Mizuno A, Yasuda S, Ogawa H, Yoshikawa T, Anzai T, Investigators for the WET-NaDEF Collaboration Project (2018) Long-term prognostic significance of plasma B-type natriuretic peptide level in patients with acute heart failure with reduced, mid-range, and preserved ejection fractions. Am J Cardiol 121(6):731–738. https://​doi.​org/​10.​1016/​j.​amjcard.​2017.​12.​012 CrossRefPubMed
49.
Zurück zum Zitat McQuade CN, Mizus M, Wald JW, Goldberg L, Jessup M, Umscheid CA (2017) Brain-type natriuretic peptide and amino-terminal pro-brain-type natriuretic peptide discharge thresholds for acute decompensated heart failure: a systematic review. Ann Intern Med 166(3):180–190. https://doi.org/10.7326/M16-1468 CrossRefPubMed McQuade CN, Mizus M, Wald JW, Goldberg L, Jessup M, Umscheid CA (2017) Brain-type natriuretic peptide and amino-terminal pro-brain-type natriuretic peptide discharge thresholds for acute decompensated heart failure: a systematic review. Ann Intern Med 166(3):180–190. https://​doi.​org/​10.​7326/​M16-1468 CrossRefPubMed
53.
Zurück zum Zitat Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, de Marco T, Escarce JJ, Evangelista LS, Hanna B, Ganiats TG, Greenberg BH, Greenfield S, Kaplan SH, Kimchi A, Liu H, Lombardo D, Mangione CM, Sadeghi B, Sadeghi B, Sarrafzadeh M, Tong K, Fonarow GC, for the Better Effectiveness After Transition–Heart Failure (BEAT-HF) Research Group (2016) Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure: the better effectiveness after transition-heart failure (BEAT-HF) randomized clinical trial. JAMA Intern Med 176(3):310–318. https://doi.org/10.1001/jamainternmed.2015.7712 CrossRefPubMedPubMedCentral Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, de Marco T, Escarce JJ, Evangelista LS, Hanna B, Ganiats TG, Greenberg BH, Greenfield S, Kaplan SH, Kimchi A, Liu H, Lombardo D, Mangione CM, Sadeghi B, Sadeghi B, Sarrafzadeh M, Tong K, Fonarow GC, for the Better Effectiveness After Transition–Heart Failure (BEAT-HF) Research Group (2016) Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure: the better effectiveness after transition-heart failure (BEAT-HF) randomized clinical trial. JAMA Intern Med 176(3):310–318. https://​doi.​org/​10.​1001/​jamainternmed.​2015.​7712 CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Boriani G, Da Costa A, Quesada A et al (2017) Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail 19(3):416–425. https://doi.org/10.1002/ejhf.626 CrossRefPubMed Boriani G, Da Costa A, Quesada A et al (2017) Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail 19(3):416–425. https://​doi.​org/​10.​1002/​ejhf.​626 CrossRefPubMed
Metadaten
Titel
Updates in heart failure 30-day readmission prevention
verfasst von
David Goldgrab
Kathir Balakumaran
Min Jung Kim
Sara R. Tabtabai
Publikationsdatum
28.11.2018
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 2/2019
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-018-9754-4

Weitere Artikel der Ausgabe 2/2019

Heart Failure Reviews 2/2019 Zur Ausgabe

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.